EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation

Yan Han, Alan Bidgoli, Brittany P DePriest, Alejandra Méndez, Khadijeh Bijangi-Vishehsaraei, Evelio D Perez-Albuerne, Robert A Krance, Jamie Renbarger, Jodi L Skiles, Sung W Choi, Hao Liu, Sophie Paczesny

JCI Insight · 22.05.2023 · 8 (10)

DOI: 10.1172/jci.insight.168221 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JCI Insight, online erschienen am 22.05.2023. Verfasst von Yan Han und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Hepatic Veno-Occlusive Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NICHD NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Currently, no laboratory tests exist to stratify for the risk of developing sinusoidal obstruction syndrome (SOS), an early endothelial complication after hematopoietic cell transplantation (HCT). Risk biomarkers of SOS have not been verified in a prospective cohort accounting for differences between practices across institutions. Herein, we aimed to define risk groups for SOS occurrence using 3 proteins: L-ficolin, hyaluronic acid (HA), and stimulation 2 (ST2). METHODS Between 2017 and 2021, we prospectively accrued 80 pediatric patients across 4 US centers. Biomarkers were tested by ELISA blind to patient groupings and associated with SOS incidence on day 35 after HCT, and overall survival (OS) on day 100 after HCT. Cutpoints were identified using retrospective cohorts and applied to the prospective cohort. RESULTS Combination of the 3 biomarkers measured on day 3 after HCT in the prospective cohort provided 80% (95% CI 55%–100%) sensitivity and 73% (95% CI 62%–83%) specificity for risk of SOS occurrence. Patients with low L-ficolin were 9 times (95% CI 3–32) more likely to develop SOS, while patients with high HA and ST2 were 6.5 (95% CI 1.9–22.0) and 5.5 (95% CI 2.3–13.1) times more likely to develop SOS. These 3 markers also predicted worse day 100 OS — L-ficolin: HR, 10.0 (95% CI 2.2–45.1), P = 0.0002; HA: HR, 4.1 (95% CI 1.0–16.4), P = 0.031; and ST2: HR, 3.9 (95% CI 0.9–16.4), P = 0.04. CONCLUSION L-ficolin, HA, and ST2 levels measured as early as 3 days after HCT improved risk stratification for SOS occurrence and OS and may guide risk-adapted preemptive therapy. TRIAL REGISTRATION ClinicalTrials.gov NCT03132337. FUNDING NIH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationHepatic Veno-Occlusive DiseaseChildHumansBiomarkersInterleukin-1 Receptor-Like 1 ProteinProspective StudiesRetrospective Studies

Stichwörter der Autor:innen

Bone marrow transplantationOncologyTransplantation

Substanzen

BiomarkersInterleukin-1 Receptor-Like 1 Protein

Autor:innen und Institutionen

  • Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Pediatrics, Children's National Medical Center, Washington, DC, USA.
  • Department of Pediatrics, Texas Children's Hospital, and Baylor College of Medicine, Houston, Texas, USA.
  • Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.

Förderung

  • NHLBI NIH HHS
  • NICHD NIH HHS
  • NCI NIH HHS

Zitieren

APA

Han, Y., Bidgoli, A., DePriest, B. P., Méndez, A., Bijangi-Vishehsaraei, K., Perez-Albuerne, E. D., Krance, R. A., Renbarger, J., Skiles, J. L., Choi, S. W., Liu, H., & Paczesny, S. (2023). Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation. JCI Insight, 8(10). https://doi.org/10.1172/jci.insight.168221

Vancouver

Han Y, Bidgoli A, DePriest BP, Méndez A, Bijangi-Vishehsaraei K, Perez-Albuerne ED, et al. Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation. JCI Insight. 2023;8(10). doi:10.1172/jci.insight.168221

BibTeX
@article{Han2023,
  author = {Han, Yan and Bidgoli, Alan and DePriest, Brittany P and Méndez, Alejandra and Bijangi-Vishehsaraei, Khadijeh and Perez-Albuerne, Evelio D and Krance, Robert A and Renbarger, Jamie and Skiles, Jodi L and Choi, Sung W and Liu, Hao and Paczesny, Sophie},
  title = {Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation},
  journal = {JCI Insight},
  year = {2023},
  volume = {8},
  number = {10},
  doi = {10.1172/jci.insight.168221}
}
Kostenlos starten →